ZGEN – Why is the ifn-lambda program in the slow lane? It looks like the drug is on target to reach the market around the time when interferon therapies will be starting to become less relevant.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”